down arrow

Pfizer Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7170811035
USD
25.70
0.13 (0.51%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

25.3525.74

52 Week

20.9127.69
Valuation
Technical
Day's Volume

CASH

35.45 M

Shareholding (Mar 2025)

FII

15.41%

Held by 651 FIIs

DII

55.64%

Held by 420 DIIs

Promoter

0.16%

How big is Pfizer Inc.?

22-Jun-2025

As of Jun 18, Pfizer Inc. has a market capitalization of $230.43 billion, with net sales of $62.46 billion and a net profit of $7.90 billion over the latest four quarters. Shareholder's funds are $88.20 billion, and total assets amount to $213.40 billion.

As of Jun 18, Pfizer Inc. has a market capitalization of 230,432.79 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 62,463.00 million, while the sum of consolidated net profit for the same period is 7,896.00 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 88,203.00 million and total assets at 213,396.00 million.

Read More

What does Pfizer Inc. do?

22-Jun-2025

Pfizer Inc. is a global biopharmaceutical company focused on the discovery, development, and manufacture of healthcare products. As of March 2025, it reported net sales of $13.7 billion and a market cap of $230.4 billion.

Overview: <BR>Pfizer Inc. is a research-based global biopharmaceutical company engaged in the discovery, development, and manufacture of healthcare products within the Pharmaceuticals & Biotechnology industry, categorized as a Large Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13,715 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2,973 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 230,432.79 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Dividend Yield: 416.53% <BR>Debt Equity: 0.50 <BR>Return on Equity: 16.06% <BR>Price to Book: 2.55<BR><BR>Contact Details: <BR>Address: 235 E 42ND ST, NEW YORK NY: 10017-5703 <BR>Tel: 1 212 5732323 <BR>Website: https://www.pfizer.com/

Read More

Who are in the management team of Pfizer Inc.?

22-Jun-2025

As of March 2022, Pfizer Inc.'s management team includes Dr. Albert Bourla as Chairman and CEO, with Mr. Shantanu Narayen as Lead Independent Director and several Independent Directors: Dr. Susan Desmond-Hellmann, Mr. Ronald Blaylock, Mr. Joseph Echevarria, and Dr. Scott Gottlieb.

As of March 2022, the management team of Pfizer Inc. includes Dr. Albert Bourla, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the Board of Directors include Mr. Shantanu Narayen as the Lead Independent Director, Dr. Susan Desmond-Hellmann, Mr. Ronald Blaylock, Mr. Joseph Echevarria, and Dr. Scott Gottlieb, all of whom hold the designation of Independent Director.

Read More

Is Pfizer Inc. overvalued or undervalued?

20-Sep-2025

As of October 29, 2024, Pfizer Inc. is considered very attractive with a P/E ratio of 15 and a PEG ratio of 0.13, indicating it is undervalued compared to peers like Eli Lilly and Merck, despite underperforming the S&P 500 with a year-to-date return of -8.97%, while offering a strong dividend yield of 428.12% and a solid ROE of 16.06%.

As of 29 October 2024, Pfizer Inc. has moved from a risky to a very attractive valuation grade. Given its current P/E ratio of 15, PEG ratio of 0.13, and EV to EBITDA ratio of 11.17, the company appears to be undervalued compared to its peers. For instance, Eli Lilly & Co. has a significantly higher P/E ratio of 40.89, while Merck & Co., Inc. stands at 15.68, indicating that Pfizer's valuation metrics are more favorable.<BR><BR>In terms of performance, Pfizer's stock has underperformed relative to the S&P 500 across multiple time frames, with a year-to-date return of -8.97% compared to the S&P 500's 12.22%. This trend reinforces the notion that Pfizer is undervalued, especially considering its strong dividend yield of 428.12% and solid ROE of 16.06%.

Read More

Is Pfizer Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Pfizer Inc. shows a mildly bullish technical trend with positive momentum indicators, but its performance has lagged behind the S&P 500, raising concerns about its strength.

As of 10 October 2025, the technical trend for Pfizer Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are also mildly bullish, supporting the overall positive stance. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly view and a bearish monthly perspective. The KST is bullish on the weekly and mildly bullish on the monthly, while the Dow Theory indicates a mildly bullish monthly trend. <BR><BR>Despite the mildly bullish indicators, Pfizer's performance has been weak compared to the S&P 500, with a -15.19% return over the past year versus the S&P's 13.36%. Overall, the current technical stance is mildly bullish, but the stock's performance relative to the benchmark raises concerns about its strength.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 16.86%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.16 times

 
3

The company has declared Positive results for the last 3 consecutive quarters

4

With ROCE of 12.73%, it has a very attractive valuation with a 1.99 Enterprise value to Capital Employed

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 235,718 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

409.58%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

18.34%

stock-summary
Price to Book

2.66

Revenue and Profits:
Net Sales:
14,653 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,903 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.73%
0%
4.73%
6 Months
9.88%
0%
9.88%
1 Year
1.86%
0%
1.86%
2 Years
-12.23%
0%
-12.23%
3 Years
-49.52%
0%
-49.52%
4 Years
-52.64%
0%
-52.64%
5 Years
-36.29%
0%
-36.29%

Pfizer Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Pfizer Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges

Pfizer Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges

Pfizer Inc. has recently revised its evaluation amid ongoing market challenges. The company's stock price is currently at $24.73, reflecting a decline over the past year. Despite some technical indicators suggesting a mildly bullish trend, Pfizer's performance has significantly lagged behind broader market indices over the past three years.

Read More
Pfizer Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

Pfizer Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

Pfizer Inc. has recently achieved a Golden Cross, indicating a potential shift in market sentiment and increased investor confidence. Despite a challenging year, recent technical indicators show bullish trends, suggesting a possible turnaround. With a market capitalization of around $155.6 billion, Pfizer remains a key player in the pharmaceuticals sector.

Read More

Is Pfizer Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Pfizer Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. The daily moving averages also indicate a mildly bullish stance. However, the monthly Bollinger Bands show a bearish signal, which tempers the overall bullish sentiment. In terms of performance, Pfizer has underperformed the S&P 500 across multiple periods, with a year-to-date return of -6.60% compared to the S&P 500's 11.41%, and a one-year return of -15.54% versus the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, but the significant underperformance relative to the benchmark raises caution....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
5.35%
EBIT Growth (5y)
7.53%
EBIT to Interest (avg)
12.68
Debt to EBITDA (avg)
2.16
Net Debt to Equity (avg)
0.50
Sales to Capital Employed (avg)
0.43
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
119.94%
Pledged Shares
0
Institutional Holding
68.68%
ROCE (avg)
16.86%
ROE (avg)
21.23%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.48
EV to EBIT
15.64
EV to EBITDA
11.17
EV to Capital Employed
1.99
EV to Sales
4.31
PEG Ratio
0.13
Dividend Yield
428.12%
ROCE (Latest)
12.73%
ROE (Latest)
16.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 264 Schemes (28.78%)

Foreign Institutions

Held by 651 Foreign Institutions (15.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 6.84% vs -22.79% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -2.35% vs 623.36% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14,653.00",
          "val2": "13,715.00",
          "chgp": "6.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,200.00",
          "val2": "6,242.00",
          "chgp": "-16.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "654.00",
          "val2": "654.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-186.00",
          "val2": "-1,338.00",
          "chgp": "86.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,903.00",
          "val2": "2,973.00",
          "chgp": "-2.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "244.00%",
          "val2": "337.10%",
          "chgp": "-9.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.84% vs -40.64% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 270.67% vs -93.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "63,627.00",
          "val2": "59,553.00",
          "chgp": "6.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "23,496.00",
          "val2": "11,582.00",
          "chgp": "102.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3,091.00",
          "val2": "2,209.00",
          "chgp": "39.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8,006.00",
          "val2": "-7,474.00",
          "chgp": "-7.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8,051.00",
          "val2": "2,172.00",
          "chgp": "270.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "259.10%",
          "val2": "88.90%",
          "chgp": "17.02%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
14,653.00
13,715.00
6.84%
Operating Profit (PBDIT) excl Other Income
5,200.00
6,242.00
-16.69%
Interest
654.00
654.00
Exceptional Items
-186.00
-1,338.00
86.10%
Consolidate Net Profit
2,903.00
2,973.00
-2.35%
Operating Profit Margin (Excl OI)
244.00%
337.10%
-9.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 6.84% vs -22.79% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -2.35% vs 623.36% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
63,627.00
59,553.00
6.84%
Operating Profit (PBDIT) excl Other Income
23,496.00
11,582.00
102.87%
Interest
3,091.00
2,209.00
39.93%
Exceptional Items
-8,006.00
-7,474.00
-7.12%
Consolidate Net Profit
8,051.00
2,172.00
270.67%
Operating Profit Margin (Excl OI)
259.10%
88.90%
17.02%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.84% vs -40.64% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 270.67% vs -93.08% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pfizer Inc. stock-summary
stock-summary
Pfizer Inc.
Pharmaceuticals & Biotechnology
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Company Coordinates stock-summary
Company Details
235 E 42ND ST , NEW YORK NY : 10017-5703
stock-summary
Tel: 1 212 5732323
stock-summary
https://www.pfizer.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."